Renal endothelial effects of antihypertensive therapy

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 5, 2004, Pages 489-493

  Delles, Christian ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Endothelium; Hypertension; Nitric oxide; Renal perfusion

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; VASOPEPTIDASE INHIBITOR;

ESSENTIAL HYPERTENSION; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SHEAR STRESS;

ANTIHYPERTENSIVE AGENTS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, RENOVASCULAR; KIDNEY; NITRIC OXIDE; REGIONAL BLOOD FLOW;

EID: 4344704364     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200409000-00002     Document Type: Review

References (35)

1. Al Suwaidi J, Homasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101:948-954.
2. Cowley AW Jr, Mori T, Mattson D, Zou AP. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 2003; 284:R1355-R1369. This review focuses on renal medullary NO production and its influence on medullary blood flow. It highlights the importance of medullary NO production for the pathogenesis of arterial hypertension.
3. Persson PB. Nitric oxide in the kidney. Am J Physiol Regul Integr Comp Physiol 2002; 283:R1005-R1007.
4. Edwards RM, Trizna W. Modulation of glomerular arteriolar tone by nitric oxide synthase inhibitors. J Am Soc Nephrol 1993; 4:1127-1132.
5. Baylis C, Qiu C. Importance of nitric oxide in the control of renal hemodynamics. Kidney Int 1996; 49:1727-1731.
6. Kramer HJ, Horacek V, Bäcker A, et al. Relative roles of nitric oxide, prostanoids and angiotensin II in the regulation of canine glomerular hemodynamics. A micropuncture study. Kidney Blood Press Res 2004; 27:10-17. This micropuncture study emphasizes the role of tonic intrarenal NOS activity to maintain renal hemodynamics.
7. Wang D, Borrego-Conde LJ, Falck JR, et al. Contributions of nitric oxide, EDHF, and EETs to endothelium-dependent relaxation in renal afferent arterioles. Kidney Int 2003; 63:2187-2193. An elegant study in isolated afferent glomerular arterioles demonstrating that endothelium-dependent vasorelaxation through acetylcholine is mediated by both NO and endothelium-derived hyperpolarizing factors.
8. Pittner J, Liu R, Brown R, et al. Visualization of nitric oxide production and intracellular calcium in juxtamedullary afferent arteriolar endothelial cells. Acta Physiol Scand 2003; 179:309-317. This study is interesting especially from a technical point of view since simultaneous visualization of NO production and intracellular calcium concentration in endothelial cells from afferent glomerular arterioles is described.
9. Grenier N, Basseau F, Ries M, et al. Functional MRI of the kidney. Abdom Imaging 2003; 28:164-175.
10. Li L, Storey P, Kim D, et al. Kidneys in hypertensive rats show reduced response to nitric oxide synthase inhibition as evaluated by BOLD MRI. J Magn Reson Imaging 2003; 17:671-675. Medullary oxygenation as assessed by blood-oxygenation-level-dependent (BOLD) magnetic resonance imaging did not change significantly in spontaneously hypertensive rats as opposed to normotensive Wistar-Kyoto rats when the NOS inhibitor L-NAME was administered indicating a reduced contribution of NO to basal renal medullary oxygenation and thereby medullary perfusion in rats.
11. Jacobi J, Schneider MP, John S, Schmieder RE. Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. J Hypertens 2002; 20:525-530.
12. G-monomethyl-L-arginine (L-NMMA), the calcium-channel blocker amlodipine (to dilate the afferent glomerular arteriole) and the angiotensin receptor blocker valsartan (to dilate the efferent glomerular arteriole) to analyze the contribution of NO to renal perfusion.
13. van den Meiracker AH, van der Linde NA, Broere A, et al. Effects of L-arginine and L-NAME on the renal function in hypertensive and normotensive subjects. Nephron 2002; 91:444-451.
14. Higashi Y, Chayama K. Renal endothelial dysfunction and hypertension. J Diabetes Complications 2002; 16:103-107.
15. Persson AE, Gutierrez A, Pittner J, et al. Renal NO production and the development of hypertension. Acta Physiol Scand 2000; 168:169-174.
16. Kumar U, Shin Y, Wersinger G, et al. Diminished expression of constitutive nitric oxide synthases in the kidney of spontaneously hypertensive rat. Clin Exp Hypertens 2003; 25:271-282. This study demonstrates reduced cortical neuronal NOS expression and reduced medullary endothelial NOS expression in spontaneously hypertensive rats as compared to Wistar-Kyoto rats. Findings are not fully in line with [17•].
17. Fernandez AP, Serrano J, Castro S, et al. Distribution of nitric oxide synthases and nitrotyrosine in the kidney of spontaneously hypertensive rats. J Hypertens 2003; 21:2375-2388. The main finding from this study is an increased medullary neuronal NOS expression in spontaneously hypertensive rats as compared to Wistar-Kyoto rats. The authors propose that this upregulation constitutes a protective mechanism to maintain renal perfusion in hypertension. Findings are not fully in line with [16•].
18. Delles C, Jacobi J, Schlaich MP, et al. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens 2002; 15:3-9.
19. Delles C, Schneider MP, Oehmer S, et al. L-arginine-induced vasodilation of the renal vasculature is not altered in hypertensive patients with type 2 diabetes. Diabetes Care 2003; 26:1836-1840.
20. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32:958-964.
21. Pereira LM, Bezerra DG, Machado DL, Mandarim-de-Lacerda CA. Enalapril attenuates cardiorenal damage in nitric-oxide-deficient spontaneously hypertensive rats. Clin Sci (Lond) 2004; 106:337-343. Enalapril was found to reduce renal structural damage in a model of genetic hypertension and NO deficiency.
22. Pereira LM, Almeida JR, Mandarim-de-Lacerda CA. Kidney adaptation in nitric oxide-deficient Wistar and spontaneously hypertensive rats. Life Sci 2004; 74:1375-1386.
23. Higashi Y, Oshima T, Sasaki S, et al. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension. Hypertension 1998; 32:16-24.
24. Vaziri ND, Wang XQ, Ni ZN, et al. Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. Biochim Biophys Acta 2002; 1592:153-161.
25. 1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats. Naunyn Schmiedebergs Arch Pharmacol 2003; 367:312-317. Simultaneous administration of losartan and fonsartan prevented an increase of blood pressure and renal insufficiency induced by chronic administration of L-NAME.
26. Delles C, Jacobi J, John S, et al. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 2002; 61:1462-1468.
27. Arima S, Kohagura K, Xu HL, et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004; 43:352-357. This is an excellent study demonstrating nongenomic vasoconstrictor effects of aldosterone in rabbit afferent glomerular arterioles that are modulated by afferent arteriolar endothelium-derived NO.
28. Hao L, Kanno Y, Fukushima R, et al. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol 2004; 24:54-60. In this model of renal hypertension, the aldosterone receptor antagonist eplerenone (but also the angiotensin receptor blocker losartan) increased endothelial NOS expression. Interestingly, eplerenone was equally effective as losartan in lowering blood pressure in this model.
29. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux:a novel mechanism for antihypertensive action. Circulation 2003; 107:2747-2752. It is demonstrated that third-generation beta blockers carvedilol and nebivolol stimulate NO release from single glomerular endothelial cells. This effect was abolished by blockade of ATP release.
30. 2 group. In contrast to propranolol, nipradilol increased urinary excretion of NO metabolites and cGMP. Glomerulosclerosis and proteinuria were also reduced in nipradilol-treated animals. Differences in renal vascular relaxation between the two drugs were not examined in this study.
31. Delles C, Schmieder RE. The kidney in congestive heart failure: renal adverse event rate of treatment. J Cardiovasc Pharmacol 2001; 38:99-107.
32. Rodriguez-Gomez I, Wangensteen R, Atucha NM, et al. Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats. Am J Hypertens 2003; 16:33-38. The vasopeptidase inhibitor omapatrilat prevents hypertension in L-NAME-treated rats. It also attenuates the increased blood pressure in a renin-independent model treated with L-NAME and deoxycorticosterone acetate.
33. Ying L, Flamant M, Vandermeersch S, et al. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats. Hypertension 2003; 42:937-944. Both captopril and omapatrilat were found to normalize blood pressure and to reduce renal injury in L-NAME-treated rats. However, both drugs were less effective when L-NAME-treated rats were put on a high-sodium diet.
34. Simko F, Matuskova J, Luptak I, et al. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 2004; 74:1211-1224. In this study chronic administration of L-NAME was used to reduce NOS activity. Treatment with simvastatin restored NOS activity.
35. Fleischmann EH, Schlaich MP, Schmidt BM, et al. Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics. Nephrol Dial Transplant 2002; 17:1758-1765.